Klebsiella pneumoniae Infections – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Klebsiella pneumoniae Infections – Drugs In Development, 2024 report and make more profitable business decisions.
Klebsiella pneumoniae is a Gram-negative bacteria. A Klebsiella pneumoniae infection is caused when the organism is able to enter the lungs, and is very common in patients with underlying diseases like diabetes, chronic lung disease, and alcoholism. It is mostly a nosocomial infection that occurs in hospitalized patients with weakened immune systems. Symptoms include necrosis, inflammation, hemorrhage, chills, dizziness, high fever, headache, and chest pain. Treatment includes antibiotics and hygienic lifestyle.
The Klebsiella pneumoniae Infections drugs in development market research report provide comprehensive information on the therapeutics under development for Klebsiella pneumoniae Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Klebsiella pneumoniae Infections and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Klebsiella pneumoniae Infections | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 64 molecules, with 53 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Klebsiella pneumoniae Infections therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Klebsiella pneumoniae Infections pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Klebsiella pneumoniae Infections treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
ABAC Therapeutics SAAEON Medix Inc
AJK Biopharmaceutical LLC
Akthelia Pharmaceuticals Ltd
Alterity Therapeutics Ltd
Armata Pharmaceuticals Inc
BB200 LLC
Bioversys AG
Celdara Medical LLC
CHO Pharma Inc
Clarametyx Biosciences Inc
ContraFect Corp
Development Center for Biotechnology
Dong-A ST Co Ltd
EffectorBio Inc
Entasis Therapeutics Holdings Inc
Evoq Nano Inc
F. Hoffmann-La Roche Ltd
Fedora Pharmaceuticals Inc
Forge Therapeutics Inc
GSK plc
Idorsia Pharmaceutical Ltd
Immunethep SA
Institute for Development Research
King's College London
LimmaTech Biologics AG
Linnaeus Bioscience Inc
Melinta Therapeutics LLC
Microbiotix Inc
Mikrobiomik Healthcare Company SL
Nektr Technologies Ltd
Neoculi Pty Ltd
Nosopharm SAS
Omniose
Pedanius Therapeutics Ltd
Peptilogics Inc
PHAXIAM Therapeutics SA
Phico Therapeutics Ltd
Planet Biotechnology Inc
Recce Pharmaceuticals Ltd
RemAb Therapeutics SL
Seres Therapeutics Inc
Shionogi & Co Ltd
Spero Therapeutics Inc
Spexis AG
Stony Brook University
Summit Therapeutics Inc
Syntiron LLC
Taisho Pharmaceutical Holdings Co Ltd
The Lundquist Institute
The National Institute of Allergy and Infectious Diseases
Tulane University
University College Dublin
University of Bern
University of Pittsburgh
Venus Medicine Research Centre
Wayne State University
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Klebsiella pneumoniae Infections reports